Shares of Unilife Corp (NASDAQ:UNIS) ended Tuesday session in red amid volatile trading. The shares closed down -0.16 points or -7.96% at $1.85 with 55,112 shares getting traded. Post opening the session at $2.02, the shares hit an intraday low of $1.83 and an intraday high of $2.07 and the price vacillated in this range throughout the day. The company has a market cap of $34.62 million and the numbers of outstanding shares have been calculated to be 17.41 million shares.
Unilife Corp (UNIS) engaged in the designing, development and manufacturing of injectable drug delivery systems. It has a portfolio of product platforms, including pre-filled syringes, wearable injectors, insulin delivery systems, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems and other systems.
Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Tuesday session in green amid volatile trading. The shares closed up +0.08 points or 0.63% at $12.69 with 8.37 million shares getting traded. Post opening the session at $12.94, the shares hit an intraday low of $12.13 and an intraday high of $12.94 and the price vacillated in this range throughout the day. The company has a market cap of $2.85 billion and the numbers of outstanding shares have been calculated to be 230.33 million shares.
Exelixis, Inc. (EXEL) announced that accomplished biopharmaceutical executive Julie Anne Smith has been elected to the company’s Board of Directors. Ms. Smith’s appointment.
Ms. Smith has nearly two decades of operational leadership experience in high growth public, private, startup, and established biopharmaceutical businesses. She currently serves as president and chief executive officer of Raptor Pharmaceuticals, a commercial-stage, global innovator in the development and commercialization of orphan disease therapies. Ms. Smith previously held key commercial and strategic leadership positions at companies including Enobia Pharma, Jazz Pharmaceuticals, and Genzyme.
“I’m delighted to welcome Julie Anne Smith to the Exelixis board of directors,” said Stelios Papadopoulos, Ph.D., an Exelixis-co-founder and chairman of the company’s board. “Her deep commercial expertise will serve Exelixis well as the company continues to execute on the launch of its latest therapy, CABOMETYX, following regulatory approval in the United States earlier this year.”